Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Madrigal Pharmaceuticals's cash was $838.75M at Jun 30, 2026. For fiscal 2025 it was $983.56M, up 5.6% from the year before. Over ten years it grew 30.9% a year on average. The highest annual figure on record is $983.56M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $983.56M | +5.6% |
| FY2024 | Dec 31, 2024 | $931.25M | +46.9% |
| FY2023 | Dec 31, 2023 | $634.13M | +76.7% |
| FY2022 | Dec 31, 2022 | $358.77M | +32.7% |
| FY2021 | Dec 31, 2021 | $270.35M | -4.9% |
| FY2020 | Dec 31, 2020 | $284.15M | -35.3% |
| FY2019 | Dec 31, 2019 | $439.05M | -9.2% |
| FY2018 | Dec 31, 2018 | $483.72M | +152.6% |
| FY2017 | Dec 31, 2017 | $191.53M | +900.4% |
| FY2016 | Dec 31, 2016 | $19.15M | -71.3% |
| FY2015 | Dec 31, 2015 | $66.60M | -31.8% |
| FY2014 | Dec 31, 2014 | $97.70M | +6.8% |
| FY2013 | Dec 31, 2013 | $91.50M | -9.0% |
| FY2012 | Dec 31, 2012 | $100.60M | +234.5% |
| FY2011 | Dec 31, 2011 | $30.08M | -3.9% |
| FY2010 | Dec 31, 2010 | $31.31M | -29.1% |
| FY2009 | Dec 31, 2009 | $44.16M | -15.2% |
| FY2008 | Dec 31, 2008 | $52.05M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $838.75M | +4.6% |
| Q1 FY2026 | Mar 31, 2026 | $812.77M | -4.2% |
| Q4 FY2025 | Dec 31, 2025 | $983.56M | +5.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.11B | +11.1% |
| Q2 FY2025 | Jun 30, 2025 | $802.02M | -24.5% |
| Q1 FY2025 | Mar 31, 2025 | $848.07M | -19.9% |
| Q4 FY2024 | Dec 31, 2024 | $931.25M | +46.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.00B | +331.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.06B | +256.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.06B | +221.4% |
| Q4 FY2023 | Dec 31, 2023 | $634.13M | +76.7% |
| Q3 FY2023 | Sep 30, 2023 | $232.35M | +51.7% |
| Q2 FY2023 | Jun 30, 2023 | $298.42M | +40.9% |
| Q1 FY2023 | Mar 31, 2023 | $329.48M | +49.8% |
| Q4 FY2022 | Dec 31, 2022 | $358.77M | +32.7% |
| Q3 FY2022 | Sep 30, 2022 | $153.20M | -48.8% |
| Q2 FY2022 | Jun 30, 2022 | $211.77M | -34.6% |
| Q1 FY2022 | Mar 31, 2022 | $219.95M | -28.4% |
| Q4 FY2021 | Dec 31, 2021 | $270.35M | -4.9% |
| Q3 FY2021 | Sep 30, 2021 | $299.14M | -11.0% |
| Q2 FY2021 | Jun 30, 2021 | $323.85M | -15.7% |
| Q1 FY2021 | Mar 31, 2021 | $307.22M | -24.8% |
| Q4 FY2020 | Dec 31, 2020 | $284.15M | -35.3% |
| Q3 FY2020 | Sep 30, 2020 | $335.94M | -25.9% |
| Q2 FY2020 | Jun 30, 2020 | $384.38M | -17.6% |
| Q1 FY2020 | Mar 31, 2020 | $408.51M | -14.5% |
| Q4 FY2019 | Dec 31, 2019 | $439.05M | -9.2% |
| Q3 FY2019 | Sep 30, 2019 | $453.61M | -7.1% |
| Q2 FY2019 | Jun 30, 2019 | $466.40M | -4.9% |
| Q1 FY2019 | Mar 31, 2019 | $477.83M | +1153.3% |
| Q4 FY2018 | Dec 31, 2018 | $483.72M | +152.6% |
| Q3 FY2018 | Sep 30, 2018 | $488.54M | +3669.6% |
| Q2 FY2018 | Jun 30, 2018 | $490.31M | +1309.0% |
| Q1 FY2018 | Mar 31, 2018 | $38.13M | +364.1% |
| Q4 FY2017 | Dec 31, 2017 | $191.53M | +900.4% |
| Q3 FY2017 | Sep 30, 2017 | $12.96M | +54.4% |
| Q2 FY2017 | Jun 30, 2017 | $34.80M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.22M | – |
| Q4 FY2016 | Dec 31, 2016 | $19.15M | – |
| Q3 FY2016 | Sep 30, 2016 | $8.39M | – |
See a number that looks wrong?